Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Director departure
Credit agrmnt [a]
Gossamer Bio, Inc. (GOSS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update - Seralutinib Phase 3 PROSERA Study in PAH Patients Expected to Initiate in 3Q23 -"
05/09/2023 8-K Quarterly results
Docs: "Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update - Feedback on Planned Registrational Program for Seralutinib Received from FDA and EMA following Successful Phase 2 TORREY Study -"
03/17/2023 8-K Quarterly results
Docs: "Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update - FDA Feedback on Seralutinib Phase 3 Clinical Trial Received&#59; Expected to Commence in the Second Half of 2023 -"
08/09/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
11/08/2021 8-K Quarterly results
Docs: "Gossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate Update - Topline Results from Ongoing Phase 2 TORREY Study of Seralutinib in Patients with PAH Now Expected in Second Half of 2022, Due to COVID-19-Related Delays -"
05/06/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update - GB004: SHIFT-UC Phase 2 trial enrolling patients with active ulcerative colitis -"
08/11/2020 8-K Quarterly results
05/12/2020 8-K Quarterly results
Docs: "Gossamer Bio Statement of Operations Condensed Consolidated Statement of Operations Three months ended March 31,"
03/24/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
Docs: "Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of September 30, 2019, were $446.5 million. The Company expects current cash, cash equivalents and marketable securities, and access to its debt facility will be sufficient to fund its operating and capital expenditures into the fourth quarter of 2021. • Research and Development Expenses: For the quarter ended September 30, 2019, R&D expenses were $40.1 million, including $2.7 million of stock-based compensation, compared to R&D expenses of $18.9 million for the quarter ended September 30, 2018. The increase was primarily due to an increase in expenses for GB001, GB002, GB004 and GB1275. • In-Process Research and Development Expenses: For the quarter ended September 30, 2019,..."
08/08/2019 8-K Quarterly results
Docs: "Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of June 30, 2019, were $464.0 million. The Company expects current cash, cash equivalents and marketable securities, and access to its debt facility will be sufficient to fund its operating and capital expenditures into the second half of 2021. • Research and Development Expenses: For the quarter ended June 30, 2019, R&D expenses were $35.7 million, including $2.5 million of stock-based compensation, compared to R&D expenses of $7.9 million for the quarter ended June 30, 2018. The increase was primarily due to costs related to the research and development of GB001, GB002, GB004 and GB1275. • In-Process Research and Development Expenses: For the quarter ended June 30, 2019, IP..."
05/14/2019 8-K Investor presentation, Quarterly results
Docs: "Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of March 31, 2019, were $481.2 million. The Company expects current cash, cash equivalents and marketable securities, and access to its debt facility will be sufficient to fund its operating and capital expenditures into the second half of 2021. • Research and Development Expenses: For the quarter ended March 31, 2019, R&D expenses were $25.0 million, including $1.3 million of stock-based compensation, compared to R&D expenses of $2.6 million for the quarter ended March 31, 2018. The increase was primarily due to costs related to the research and development of GB001, GB002 and GB004. • In-Process Research and Development Expenses: For the quarter ended March 31, 2019, IPR&D ...",
"Slide Presentation"
03/22/2019 8-K Quarterly results
Docs: "Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of December 31, 2018 were $228.7 million. Subsequent to year end, Gossamer raised approximately $295.2 million in its IPO, net of underwriting discounts. • Research and Development Expenses: For the year ended December 31, 2018, R&D expenses were $55.3 million, which included $6.0 million of costs related to personnel and external consultants. • In-Process Research and Development Expenses: For the year ended December 31, 2018, IPR&D expenses were $49.7 million, which was primarily attributable to approximately $27.5 million of costs related to up-front in-licensing and product acquisition payments related to GB004 and GB1275, and $19.1 million of costs associated with the is..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy